Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study

Richard S. Finn, Carmelo Bengala, Nuhad Ibrahim, Henri Roche, Joseph Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy, Lori J. Goldstein

Research output: Contribution to journalArticle

121 Scopus citations

Abstract

Purpose: Dasatinib is a potent, oral SRC-family kinase inhibitor with preclinical antiproliferative, antimetastatic, and antiosteoclastic activity suggesting dasatinib sensitivity in triple-negative, or basal-like, breast cancer cell lines. This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer (TNBC). Experimental Design: Female patients with measurable, locally advanced or metastatic TNBC initially received dasatinib 100 mg twice daily (BID); to improve tolerability, the protocol was amended and subsequent patients received 70 mg BID. Primary endpoint was Response Evaluation Criteria in Solid Tumors-defined objective response rate (ORR); secondary endpoints included progression-free survival (PFS), disease control rate (DCR), safety, and limited pharmacokinetics. Results: Of the 44 treated patients, 43 were response evaluable. ORR was 4.7%: two patients had confirmed partial responses lasting 14 and 58 weeks, respectively. Of 11 patients with stable disease, two continued for more than 16 weeks, thus protocol-defined DCR was 9.3%. Median PFS was 8.3 weeks (95% CI: 7.3-15.3). Five patients discontinued before first tumor assessment. No grade 4 adverse events (AE) were reported; grade 3 AEs occurring in more than 5% of patients were fatigue (9.1%), diarrhea, pleural effusion, and dyspnea (all 6.8%). Laboratory abnormalities were uncommon. Dasatinib at 100 mg BID was not well tolerated; rates of treatment interruption, dose reduction, and serious AEs were lower with dasatinib 70 mg BID. Conclusions: Single-agent dasatinib has limited activity in unselected patients with TNBC. Dasatinib 70 mg BID was better tolerated than 100 mg BID. Future studies will investigate dasatinib in other breast cancer settings, including chemotherapy combinations.

Original languageEnglish (US)
Pages (from-to)6905-6913
Number of pages9
JournalClinical Cancer Research
Volume17
Issue number21
DOIs
StatePublished - Nov 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Finn, R. S., Bengala, C., Ibrahim, N., Roche, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011). Dasatinib as a single agent in triple-negative breast cancer: Results of an open-label phase 2 study. Clinical Cancer Research, 17(21), 6905-6913. https://doi.org/10.1158/1078-0432.CCR-11-0288